Cassava Sciences, Inc. (SAVA) News
Filter SAVA News Items
SAVA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SAVA News Highlights
- For SAVA, its 30 day story count is now at 8.
- Over the past 19 days, the trend for SAVA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, DRUG and MD are the most mentioned tickers in articles about SAVA.
Latest SAVA News From Around the Web
Below are the latest news stories about CASSAVA SCIENCES INC that investors may wish to consider to help them evaluate SAVA as an investment opportunity.
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall StreetWall Street analysts foresee up to 316% upside in three fast-paced companies in the new year. |
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Why Cassava Sciences Stock Zoomed 21% Higher This WeekThe company has chosen an offbeat way to keep its investors sweet. |
Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up DaysCassava Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 88. The company earns the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group. |
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?Although Cassava Sciences’ issuance of warrants presents risks, the underlying Phase 3 trial support boosted SAVA stock. |
Cassava Sciences Announces Dividend Distribution of Warrants to ShareholdersShareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of ChargeWarrants Are Expected to List and Trade on NasdaqWarrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced a pro rata dividend distribution of warra |
Why Cassava Sciences Stock Soared TodayAmbitious biotech Cassava Sciences (NASDAQ: SAVA) had a fine Friday on the stock market, with its shares closing more than 17% higher. Cassava, which concentrates its efforts on treatments for Alzheimer's disease, said that it had appointed three new members to its board of directors. Of the trio, two are seasoned veterans in the healthcare industry, and the third has notable experience in cybersecurity and emergency-response management. |
Cassava Sciences Appoints Three New Members to its Board of DirectorsDr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted i |
7 High-Risk, High-Reward Stocks for the Extreme ContrarianAlthough the general concept of stock picks for contrarian investors may be universally appealing, when it comes to the most extreme examples, most investors should probably stay away. |
Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s... |